- Vertex Pharmaceuticals (Nasdaq: VRTX) is a leading biotechnology company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies for cystic fibrosis and other serious diseases, with a market cap of $112.9 billion.
- In April 2026, Vertex received FDA approval for expanded label extensions of its cystic fibrosis treatments ALYFTREK® and TRIKAFTA®, allowing approximately 95% of people with CF in the U.S. to access these therapies.
- Vertex has established strategic collaborations and partnerships to advance its research pipeline, including new therapies for sickle cell disease and beta-thalassemia, contributing to its projected revenue of $12.95 billion to $13.1 billion for 2026.
- Sales teams should focus on healthcare providers and institutions treating cystic fibrosis patients, as Vertex's therapies address critical patient needs and are positioned for significant market growth with the recent FDA approvals.
Vertex Pharmaceuticals has a diverse departmental structure, with a total of 19 departments. The largest departments include Engineering with 716 employees, Operations at 657, and Executive roles comprising 551 individuals. This distribution indicates a strong emphasis on technical and operational capabilities, supporting the company's focus on innovation and efficiency in the pharmaceutical industry.
The workforce is geographically concentrated, with the largest presence in Boston, MA, housing 1,394 employees, followed by Cambridge, MA, with 653 employees. Other significant locations include San Diego, CA, with 305 employees, and a notable 'Other' category that comprises 2,446 employees across various regions. This distribution suggests a strategic focus on key innovation hubs while maintaining a distributed workforce across multiple sites.
